As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
Subscribe To Our Newsletter & Stay Updated
